Taysha Gene Therapies Inc (TSHA)
3.09
-0.05
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
3.08
-0.01
(-0.32%)
After-Hours: 20:00
Taysha Gene Therapies Total Liabilities (Quarterly): 99.15M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 99.15M |
December 31, 2023 | 97.79M |
September 30, 2023 | 244.88M |
June 30, 2023 | 118.66M |
March 31, 2023 | 116.55M |
December 31, 2022 | 125.33M |
September 30, 2022 | 100.34M |
June 30, 2022 | 109.62M |
Date | Value |
---|---|
March 31, 2022 | 115.25M |
December 31, 2021 | 118.57M |
September 30, 2021 | 100.65M |
June 30, 2021 | 55.36M |
March 31, 2021 | 19.96M |
December 31, 2020 | 7.579M |
September 30, 2020 | 11.62M |
June 30, 2020 | 20.09M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
7.579M
Minimum
Dec 2020
244.88M
Maximum
Sep 2023
91.34M
Average
100.50M
Median
Total Liabilities (Quarterly) Benchmarks
Aquestive Therapeutics Inc | 165.82M |
Lifecore Biomedical Inc | 256.99M |
Relmada Therapeutics Inc | 12.36M |
ACADIA Pharmaceuticals Inc | 391.06M |
Cyclacel Pharmaceuticals Inc | 8.198M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 153.00M |
Shareholders Equity (Quarterly) | 53.85M |
Debt to Equity Ratio | 0.7523 |
Current Ratio | 3.380 |
Net Debt Paydown Yield | -0.09% |